Clinical Trial Results:
Preventing cognitive decline and dementia from cerebral
small vessel disease
Summary
|
|
EudraCT number |
2015-001953-33 |
Trial protocol |
GB |
Global end of trial date |
31 Jul 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Dec 2019
|
First version publication date |
18 Dec 2019
|
Other versions |
|
Summary report(s) |
Fronteirs paper EClinical Medicine paper |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
PrevSVD-2015
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN12580546 | ||
US NCT number |
NCT02481323 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
Alzheimer's Society: 252 (AS-PG-14-033) | ||
Sponsors
|
|||
Sponsor organisation name |
University of Edinburgh
|
||
Sponsor organisation address |
Little France Crescent, Edinburgh, United Kingdom, EH16 4TJ
|
||
Public contact |
Trial Manager (Kirsten Shuler), University of Edinburgh, 44 131 465 9599, joanna.wardlaw@ed.ac.uk
|
||
Scientific contact |
Prof Joanna Wadlaw, University of Edinburgh, 44 131 465 9599, joanna.wardlaw@ed.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
17 Nov 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
31 Oct 2017
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Jul 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
We propose to do a small clinical trial to test how well Cilostazol and ISMN are tolerated by lacunar stroke patients when given individually or in combination, at increasing doses. We will monitor symptoms like headache, heart thumping, dizziness, bruising, other brain and leg symptoms, to see how patients find taking the drugs.
|
||
Protection of trial subjects |
Participants take trial medication for 11 weeks. The dose is increased, in weekly increments over two to three weeks as tolerated, sustained until eight weeks post-randomization, then decreased gradually over two weeks and stopped. The escalating dose is designed to reduce potential adverse effects following initiation of cilostazol and is standard for ISMN. Gradual dose reduction aims to prevent large hemodynamic changes on cessation of medication
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
02 Nov 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 57
|
||
Worldwide total number of subjects |
57
|
||
EEA total number of subjects |
57
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
27
|
||
From 65 to 84 years |
27
|
||
85 years and over |
3
|
|
||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||
Recruitment details |
- | |||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||
Screening details |
- | |||||||||||||||||||||||||
Pre-assignment period milestones
|
||||||||||||||||||||||||||
Number of subjects started |
57 | |||||||||||||||||||||||||
Number of subjects completed |
57 | |||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||
Period 1 title |
treatment phase (overall period)
|
|||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Assessor | |||||||||||||||||||||||||
Blinding implementation details |
To maintain blinding of participants, prior to the start of the trial, the Investigational Supplies Group (ISG), an independent arm of the Research and Development Office, NHS Lothian, removed study medications from their original blister packs and placed them in bottles labelled‘ Drug A’ or ‘Drug B’, a process which was approved by the Medicines and Healthcare Regulatory Agency.
|
|||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||
Arm title
|
cilostazol | |||||||||||||||||||||||||
Arm description |
cilostazol alone, 50 mg twice daily, increasing to 100 mg twice daily | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
cilostazol
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||
Dosage and administration details |
50mg twice daily increasing to 100mg twice daily
|
|||||||||||||||||||||||||
Arm title
|
ISMN | |||||||||||||||||||||||||
Arm description |
ISMN alone, 25 mg once daily increasing to 25 mg twice daily | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
Isosorbide Mononitrate
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||
Dosage and administration details |
25mg od increasing to 25mg bd
|
|||||||||||||||||||||||||
Arm title
|
both, immediate start | |||||||||||||||||||||||||
Arm description |
Cilostazol and ISMN combined, started immediately, ISMN given first | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
cilostazol
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||
Dosage and administration details |
50mg twice daily increasing to 100mg twice daily
|
|||||||||||||||||||||||||
Investigational medicinal product name |
Isosorbide Mononitrate
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||
Dosage and administration details |
25mg od increasing to 25mg bd
|
|||||||||||||||||||||||||
Arm title
|
both, delayed | |||||||||||||||||||||||||
Arm description |
cilostazol and ISMN combined, start delayed for three weeks, cilostazol given first. | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
cilostazol
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||
Dosage and administration details |
50mg twice daily increasing to 100mg twice daily
|
|||||||||||||||||||||||||
Investigational medicinal product name |
Isosorbide Mononitrate
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||
Dosage and administration details |
25mg od increasing to 25mg bd
|
|||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
treatment phase
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
analysis set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
one patient withdrew from study
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
cilostazol
|
||
Reporting group description |
cilostazol alone, 50 mg twice daily, increasing to 100 mg twice daily | ||
Reporting group title |
ISMN
|
||
Reporting group description |
ISMN alone, 25 mg once daily increasing to 25 mg twice daily | ||
Reporting group title |
both, immediate start
|
||
Reporting group description |
Cilostazol and ISMN combined, started immediately, ISMN given first | ||
Reporting group title |
both, delayed
|
||
Reporting group description |
cilostazol and ISMN combined, start delayed for three weeks, cilostazol given first. | ||
Subject analysis set title |
analysis set
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
one patient withdrew from study
|
|
|||||||||||||||||||
End point title |
proportion of patients reaching target dose | ||||||||||||||||||
End point description |
The primary outcome was the proportion of participants achieving target dose by the end of the eight-week trial period, assessed by structured questionnaire
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
8 weeks from randomisation
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
SAP | ||||||||||||||||||
Statistical analysis description |
provided in the study protocol at https://doi.org/10.1177/1747493017731947
|
||||||||||||||||||
Comparison groups |
ISMN v both, immediate start v cilostazol v both, delayed
|
||||||||||||||||||
Number of subjects included in analysis |
56
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
other [1] | ||||||||||||||||||
P-value |
< 0.05 [2] | ||||||||||||||||||
Method |
difference in proportions | ||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||
Point estimate |
3.97
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.98 | ||||||||||||||||||
upper limit |
14.46 | ||||||||||||||||||
Variability estimate |
Standard deviation
|
||||||||||||||||||
Notes [1] - safety and tolerability [2] - ... in proportion reaching target dose |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
baseline, treatment phase
|
||
Adverse event reporting additional description |
patient self report at weekly FU
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
physician self compl | ||
Dictionary version |
1
|
||
Frequency threshold for reporting non-serious adverse events: 1.8% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Symptoms were common without trial medication. In the week prior to randomisation, the following symptoms were experienced: headache 30%; palpitations 20%; dizziness 40%; loose stools 30%; nausea 15%; dyspepsia 45%; bruising 20%; bleeding from mucous membranes 15%; and rash 9%. Following drug initiation, there was a slight increase in headache, palpitations, dizziness, loose stools, nausea, followed by a return to baseline levels with continued trial drug (Fig. 3; Table 2; Supplementary Fig. S3) |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/31317131 http://www.ncbi.nlm.nih.gov/pubmed/31333572 http://www.ncbi.nlm.nih.gov/pubmed/28906205 |